| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2144558 | Lung Cancer | 2006 | 7 Pages |
Abstract
This schedule of pemetrexed plus gemcitabine is tolerable and offered the advantage of not requiring a 90-min delay between the two drugs. Response rate, survival, time to disease progression, and toxicity were acceptable and similar to other NSCLC regimens.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Joseph Treat, Philip Bonomi, Michael McCleod, Neal P. Christiansen, David M. Mintzer, Matthew J. Monberg, Zhishen Ye, Ruqin Chen, Coleman K. Obasaju,